Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia

Abstract

This invited review summarizes the results of an international study using gene expression profiling to identify patients with unmutated IGHV who might benefit from first-line FCR chemoimmunotherapy.

Keywords

• chronic lymphocytic leukemia
• prognosis - chemoimmunotherapy
• IGHV mutational status
• gene expression profiling